AUTHORS
Andrew Artz, MD,MS, Heidi Klepin, MD2, Can-Lan Sun, Ph.D.3, Heeyoung Kim, MS4, Geoffrey Shouse, DO PhD5, Briana Campus, BS6, Reed Friend, MD7, Nini Huynh8, Murali Janakiram, MBBS9, Trenton Jarzomkowske10, Letha Miller, BS, CMA11, Chuck Oshea, BS12, Nidhi Sharma, MS, Ph.D13, Rakhee Vaidya, MD14, William Dale, MD, Ph.D15, Ashley Rosko, MD16
AFFILIATIONS
1 City of Hope, Duarte, California, United States
2 Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
3 City of Hope, Duarte, California, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
8 City of Hope, Duarte, California, United States
9 City of Hope, Duarte, California, United States
10 Atrium Health Wake Forest Babtist, Winston Salem, North Carolina, United States
11 City of Hope, Duarte, California, United States
12 City of Hope, Duarte, California, United States
13 The James Comprehensive Cancer Center, Columbus, Ohio, United States
14 Wake Forest School of Medicine, Winston Salem, North Carolina, United States
15 City of Hope, Duarte, California, United States
16 The Ohio State University, Columbus, Ohio, United States
ABSTRACT
Background and Significance. CAR T cell therapy is associated with high response rates in relapsed and/or refractory B-cell non-Hodgkin Lymphoma (NHL) and multiple myeloma (MM) however significant toxicities; namely cytokine release syndrome (CRS) and neurological toxicities remain. A major gap exists in understanding recovery from these toxicities for older adults with no specific interventions established to reduce older adult morbidity and/or functional recovery. Geriatric assessment (GA) to identify aging-related impairments accompanied by targeted interventions has been demonstrated to reduce chemotherapy related toxicity among older outpatients being treated primarily for solid tumors and is recommended by national guidelines. (Dale W., J Clin Oncol. 2023:41) Limited data exist on GA in the CAR T setting and aging-guided approaches to circumvent morbidity and toxicity are lacking. We hypothesized that a CAR T specific GA-guided multi-disciplinary optimization strategy initiated before and continuing after CAR T would attenuate early functional decline, cognitive impairment, and malnutrition.
Study Design and Methods: GOCART is a multi-institutional prospective randomized phase II trial (NCT06052826) testing whether a CAR T specific GA-guided optimization will improve functional recovery compared to standard of care (SOC). The study population includes patients ≥ 60 years of age planned for commercial CAR T for NHL or MM. The trial is on-going at 3 academic centers encompassing 5 hospitals in the United States. CAR T eligibility is determined by the institution and treating physicians. Exclusion criteria include prior CAR T, inability to complete study procedures, non-English language except Spanish and Mandarin. Patients undergo the Cancer and Aging Research Group GA augmented by CAR T relevant tools of function by short physical performance score (SPPB), cognition by Montreal Cognitive Assessment (MoCA), nutrition by Mini-Nutritional Assessment and frailty by Fried Frailty Phenotype. The GA and synopsis is sent to the treating physicians. Patients are randomized 1:1 to SOC versus study coordinated GA optimization. SOC may consult and refer as indicated. For GA optimization, subjects undergo GA-informed interventions of function by physical therapy, cognition by occupational therapy or geriatrics, and nutrition by a dietician. GA-targeted optimization comprises three phases: (i) submitting GA to both primary physician and optimization specialists to review, (ii) initial optimization guided by GA results prior to lymphodepletion, and (iii) continuation therapy after lymphodepletion through 4 weeks post CAR T infusion. The primary endpoint is the rate of functional recovery at day 30 quantified by SPPB change score from baseline. Secondary endpoints include rate of cognitive impairment, malnourishment, Frailty Phenotype progression, CAR T toxicities, response, overall survival and progression-free survival. The target accrual is 164 subjects to achieve 146 evaluable subjects which provides 80% power to detect a between-group SPPB change score of 1.25 with a two-sided alpha level of 0.05. Evaluability requires completion of baseline SPPB and starting lymphodepletion. We have accrued 154 patients to date.
The study is the first randomized geriatric targeted optimization strategy in the CAR T setting. The study emphasizes multidisciplinary interventions peri CAR T to mitigate complications from geriatric limitations aiming to improve functional recovery and geriatric morbidity. The study will further inform baseline rates of geriatric deficits and uptake of referrals after receiving pre CAR T GA in the SOC arm. If the trial endpoint is met, the GOCART trial will establish an evidence-based GA guided supportive care strategy to reduce geriatric morbidity among older adults receiving CAR T therapy which may encourage broader access.
DISCLOSURES
Andrew Artz, MD,MS: Arog Pharmaceuticals - Consultancy (Includes expert testimony); Takeda Pharmaceuticals - Consultancy (Includes expert testimony); CSL Vifor - Consultancy (Includes expert testimony); Daichii Sankyo - Consultancy (Includes expert testimony)